South Korean medical aesthetic device company SHENB successfully held the official launch event for its new product, PLADUO, in Moscow, Russia, on May 18. The event, held in the heart of Moscow, welcomed over 350 attendees, including local physicians and key industry figures, underscoring the high level of interest in the new device. Far from a conventional product showcase, the event featured a diverse lineup of programs designed to demonstrate the clinical effectiveness and advanced technology of PLADUO. Expert-led presentations offered in-depth explanations of the device's mechanism and clinical results, while live treatment demonstrations using the actual equipment drew enthusiastic responses from the audience.

The event stood out with its unique theme inspired by the Men in Black film. Staff members dressed in black suits and a stage design reminiscent of a sci-fi movie created an engaging and memorable atmosphere, distinguishing the launch from traditional medical device presentations.

PLADUO is SHENB's next-generation dual plasma medical device, developed with the company's proprietary technology. It is capable of simultaneously using nitrogen (N₂) plasma and argon (Ar) plasma, offering enhanced versatility for medical aesthetic treatments. The device features SHENB's patented Spinshot system, which ensures consistent and stable plasma generation. With 15 levels of energy control, it enables practitioners to deliver precise energy tailored to each procedure.

Notably, PLADUO has obtained both CE certification in Europe and FDA approval in the United States, demonstrating its compliance with global safety and efficacy standards and thereby enhancing its credibility in international markets.

A SHENB representative stated, "Following the success of VirtueRF, PLADUO represents our next strategic flagship product. The Russian launch marks a significant milestone in demonstrating our brand's global competitiveness." The spokesperson added, "Russia is one of the key markets in Europe with steadily growing demand for medical aesthetics. We plan to strengthen our market presence through ongoing collaboration and training programs with local medical professionals."

They further revealed, "We are also actively preparing for the U.S. launch. By conducting thorough market analysis and taking a strategic approach, we aim to ensure PLADUO achieves the same level of success as VirtueRF in the U.S. market."